Skip to main content

Thiazolidinedione

Close up of mixed medications

12-09-2022 | Medications | News

TriMaster data support ‘try before you choose’ for type 2 diabetes medications

Allowing people to try out medications for type 2 diabetes and choose their preferred one is a viable approach in the absence of a clear clinical indication, say the TriMaster investigators.

10-14-2022 | Dementia | News

Glitazone use linked to reduced dementia risk in type 2 diabetes

People aged 60 years or older receiving thiazolidinedione monotherapy for type 2 diabetes may have a lower risk for dementia than those taking metformin monotherapy, an observational study suggests.

Arrow on target

09-29-2021 | EASD 2021 | Conference coverage | News

TriMaster supports precision medicine strategy for type 2 diabetes treatment intensification

Findings from the TriMaster trial suggest that stratification of people with type 2 diabetes based on clinical features may help to guide the choice of second- or third-line drug for those who require treatment intensification after metformin.

Brain scan

04-08-2021 | Stroke | News

Genetic analysis backs causal link between blood glucose and stroke

A Mendelian analysis supports a causal effect of hyperglycemia on stroke risk, and the researchers also pinpoint the medications most likely to reduce this risk.

02-06-2020 | Rosiglitazone | News

Individual patient data analysis firms up rosiglitazone safety verdict

An individual patient data meta-analysis confirms the increased heart failure risk associated with rosiglitazone and lends some support to an elevated myocardial infarction risk.

01-31-2020 | Cardiovascular outcomes | News

Cardiovascular risks, benefits of different diabetes drugs quantified

An umbrella review of meta-analyses has demonstrated mixed associations between different glucose-lowering agents and cardiovascular outcomes in people with type 2 diabetes, with the results favoring sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists as cardioprotective agents.

Pills_two types

09-17-2018 | Prediabetes | medwireNews | News

Targeting pathophysiology from outset may slow progression to type 2 diabetes

Upfront treatment with medications that target the underlying pathophysiology of prediabetes may slow patients’ progression to type 2 diabetes, report researchers.

08-09-2018 | Medications | News

Sex, BMI influence response to common second-line diabetes medications

Researchers have used data from clinical practice and randomized trials to identify simple predictors of patient response to sulfonylureas and thiazolidinediones.